Exercise may counteract side effects of prostate cancer hormone therapy

NCT ID NCT07680920

Not yet recruiting Symptom relief Sponsor: Universidade Federal de Santa Catarina Source: ClinicalTrials.gov ↗

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This trial investigates whether a supervised program of aerobic and strength training can improve quality of life, heart function, and body composition in men with prostate cancer who are receiving androgen deprivation therapy (hormone therapy). The study involves 46 men aged 40 to 75 with stage I-III prostate cancer. Participants will be randomly assigned to either a 12-week supervised exercise group or a control group. Researchers will measure changes in quality of life, physical function, blood pressure, and body fat before and after the program.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: supervised combined aerobic and strength training
What this could lead to: If effective, supervised exercise could become a standard way to reduce side effects of hormone therapy for prostate cancer, improving daily life and heart health.
What could go wrong: This is a small, early-stage trial with only 46 participants, so results may not apply to all patients. Exercise may not significantly improve all measured outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANDROGEN-DEPRIVATION THERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Motor Activity prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANDROGEN-DEPRIVATION THERAPY PROSTATE CANCER PATIENTS

More trials for these conditions

Other studies related to the condition(s) this trial covers.